AC
KYNB

Armistice Capital’s Kyntra Bio KYNB Stock Holding History

Armistice Capital’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-40,000
Closed -$892K – 284
2024
Q2 		$892K Hold
40,000
– – 0.01% 166
2024
Q1 		$2.35M Buy
+40,000
New +$1.72M 0.03% 139

Other funds holding KYNB

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Armistice Capital's KYNB Position: Q1 2026 in Review

Armistice Capital held its Kyntra Bio (KYNB) position steady in Q1 2026 at 400,000 shares worth $2.71M. The position accounts for 0.05% of the portfolio, ranked #147.

Armistice Capital first reported a position in KYNB in Q2 2022 and has held it in 16 quarters since. The position peaked at $61.9M in Q4 2022. 32 funds tracked by Wall St. Rank hold KYNB as of Q1 2026.

  • Armistice Capital held 400,000 shares of Kyntra Bio worth $2.71M as of Q1 2026.
  • Armistice Capital left its Kyntra Bio share count unchanged in Q1 2026.
  • Kyntra Bio made up 0.05% of Armistice Capital's portfolio in Q1 2026, its #147 holding.
  • Armistice Capital first reported a position in Kyntra Bio in Q2 2022 and has held it in 16 quarters since.
  • Armistice Capital's Kyntra Bio position peaked at $61.9M in Q4 2022.
  • 32 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.